INTRODUCTION
Type 2 diabetes is a complex metabolic disorder with both genetic and environmental factors such as food habits and lifestyle contributing to its pathogenesis [1] . Due to its complex aetiology, the progress of discovery of genetic components for Type 2 diabetes had been very slow until the advent of high throughput genome-wide association (GWA) studies [2] [3] . Most individuals with T2DM suffer serious complications of chronic hyperglycemia, involved in nephropathy, neuropathy, retinopathy, and accelerated development of cardiovascular disease. When the micro vascular complications are related to the degree of fasting hyperglycemia [4] , macro vascular complication like atherosclerosis is related to postprandial glycemic level [5] . One of the regulators of postprandial glucose level is GLP-1.
The importance of gastrointestinal hormones to augment insulin secretion following nutrient ingestion, termed the incretin effect, has generated renewed interest in recent years [6] [7] [8] of the many putative insulin-stimulatory factors released by the gut, glucagon-like peptide 1 (GLP-1) has received considerable attention because of its potency to lower blood glucose in persons with diabetes and the potential of therapeutics based on the GLP-1 signalling system [7] [8] . It is produced in the L cells of gut and brain, and it stimulates insulin secretion and lowers blood glucose in both normal subjects and patients with NIDDM [9] [10] . Remarkably, GLP-1 infusion also lowered blood glucose in patients with tissues [14] [15] [16] , actions that would also contribute to lowering blood glucose in vivo. The precursor of GLP-1 is preproglucagon, which is also the precursor of glucagon of α cell of pancreas. In L cells of small intestine, preproglucagon is getting processed to form GLP-1, GLP-2 and glicentin. Tissue specific difference in processing preproglucagon is explained by a tissue specific expression of an enhancer TCF7L2 (Transcription factor 7 -like 2) Transcription factor 7-like 2 (TCF7L2) gene spans a 215,863 bases region on chromosome 10q25.317 (114700201-114916063, NCBI build 36.2 [17] , and its product is a high-mobility box-containing transcription factor that has a role in activating many genes downstream of the Wnt signalling pathway [18] [19] [20] [21] . The bipartite transcription factor, cat/TCF7L2, activates many genes downstream of the Wnt signalling cascade [51] . One of the genes transcriptionally regulated by cat/TCF7L2 is proglucagon, which encodes the insulinotropic hormone glucagon-like peptide 1 (GLP-1) [20] [21] . The tissue specific expression of GLP-1 is explained by the fact that Glycogen synthase β binds to TCF7L2 regulator sequence, which is in euchromatin region only in gut cells followed by expression of the transcription factor 7L2 which helps in transcription and processing of preproglucagon to form GLP-1 [22] .
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There is now growing evidence that, based on the role of TCF7L2 in intestinal cells [22] Grant et al. [23] proposed that variants of TCF7L2 may alter levels of glucagon-like peptide 1, which influences insulin secretion [6] [7] [8] from the β cells of the pancreas or insulin sensitivity [24] [25] [26] . Thus, one hypothesis is that TCF7L2 might influence the risk of Type 2 diabetes by influencing insulin secretion and action, by altering GLP-1 level.
Indeed, several studies have reported reduced insulin secretion after an oral glucose tolerance test (OGTT) in subjects with TCF7L2 variants, using ratios between insulin and glucose levels such as insulinogenic index [24] [25] [26] . Reduced insulin secretion in response to oral compared with intravenous glucose has also been reported among subjects with TCF7L2 variants [27] [28] , consistent with alterations in the incretin system. However, several studies have shown no change in insulin sensitivity [25] [27] , whereas other studies have shown increased [24] [30] or decreased [28] [29] insulin sensitivity. The present study was undertaken to clarify the effect of TCF7L2 on insulin secretion and sensitivity and in turn on the risk of Type 2 diabetes.
MATERIALS AND METHODS

Study Population
Cases
The study sample comprised 90 south Indian newly diagnosed Diabetic patients (163 male, 18 female) of mean age 50.34 + 9.84 years.
Inclusion criterion 31 were, 
Exclusion Criteria
 Secondary causes of diabetes like hyperthyroidism, acromegaly, pheochromocytoma were excluded  Known diabetic patients on treatment were excluded to avoid the interference of glucose toxicity with insulin secretion32.
Control Subjects
Controls were recruited from people attending the master health check. Age and Sex were matched.
Methods
Height, weight, waist circumference and hip circumference were measured, and blood samples were collected by Venipuncture after overnight fasting in both a plain tube and the tube with sodium fluoride and potassium oxalate. Plain tube was centrifuged at 2000 rpm for 10 minutes and serum was aliquoted in two tubes and one was used for estimation of fasting insulin levels and the other for GLP-1 levels into which a DPPIV inhibitor [33] was added. Fluoride and oxalate tubes were centrifuged at 2000 rpm for twenty minutes to get the buffy coat for DNA extraction and the plasma was used for fasting plasma glucose estimation. Post prandial blood samples were collected 2 hours after giving 100 g of glucose dissolved in 75 mL of water in plain and sodium fluoride -potassium oxalate tubes. Plain tube was centrifuged at 2000 rpm for 10 minutes and serum was aliquoted in two tubes and one was used for estimation of postprandial insulin and the other for GLP-1 levels into which a DPPIV inhibitor was added. Fluoride, oxalate tube was centrifuged at 2000 rpm for ten minutes and the plasma was used for post prandial plasma glucose estimation.
 Fasting and postprandial plasma glucose was measured by glucose oxidase peroxide method with an auto analyzer (XL 300) and manufacturers Agent kits.  Fasting and postprandial Insulin were measured using a sandwich immunoassay.
 Fasting and postprandial bioactive GLP-1 (7-36) levels were measured using a sandwich immunoassay.  Fasting insulin and glucose levels were used to measure HOMA-IR using a formula, HOMA-IR = Fasting insulin (mIU/L) X Fasting plasma glucose (mM) 22.5 % rise in insulin was calculated.  To remove the effect of confounding factors of insulin resistance [34], Body Mass Index and waist Hip Ratio were calculated and compared.
TCF-7L2 Polymorphism Screening
DNA was extracted from buffy coat by spin column based Himedia HiPer™ gel extraction kit method. The extracted DNA was checked in 1% agarose gel with a high molecular weight ladder, quantitated based on absorbance at 260 nm and was used for Real Time PCR  20 mg of genomic DNA will be amplified in each assay in the presence of specific probes for each SNP variant labelled with fluorescent dye at the 5' end and a quencher molecule at the 3' end (designed by Applied Bio systems' "assays-by-design" service). Allele C was VIC labelled and T was FAM labelled  PCR will be carried out in 1 μl reaction volumes with 1× Absolute™ PCR mix (ABgene) and 1× probe mix (Applied Bio systems).  An initial denaturation at 95°C for 10 minutes to be followed by 40 cycles of PCR, with 15 seconds denaturation at 95°C, and 1-minute annealing/extension at 60°C.  Following 40 cycles of PCR, fluorescence will be measured for each probe on a Pherastar plate reader and compared with an internal control ROX dye standard. Table 1 shows Age, Sex, BMI, WHR, fasting and postprandial glucose, insulin and GLP-1 levels among patients and control subjects. Since all the confounding factors were matched there were no significant differences between the two groups. Significant differences could be observed with respect to fasting and postprandial glucose, insulin and GLP-1 levels 
Table1. Characteristics of Patients with Type 2 Diabetes and of Control Subjects.
Variables
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Page 13  Table 5 shows the difference in GLP-1 level between the various genotypes.  Table 6 shows that among both cases and controls, HOMA-IR is high among T+ genotypic individuals when compared to T-individuals, postprandial insulin % rise in insulin are low among T+ genotypic individuals when compared to T-individuals. 
Table6. Correlation between Genotype and Insulin Levels and Sensitivity.
Group
DISCUSSION
Genetic factors in combination with several environmental risk factors are involved in the predisposition to Type 2 Diabetes mellitus. The susceptibility to Type 2 Diabetes is complex and recently significance is given to the role of incretins particularly GLP-1 in glycemic control, with the advent of therapeutics aimed at increasing GLP-1 levels, because GLP-1 is found to increase insulin release in response to food in the gut. Some studies have proven that GLP-1 increases insulin sensitivity [26] [27] [28] but some studies defer the concept [25] . Another interesting aspect of GLP-1 synthesis is that it shares the same precursor as that of glucagon which is preproglucagon. Preproglucagon gets differentially processed in the two tissues to give rise to two different products -GLP-1 in L cells of small intestine and glucagon in alpha cells of pancreas. This differential processing is explained by the tissue specific expression of enhancer TCF7L2 [22] with a known polymorphic site in intron 6 [32] . Normally, rs7903146 site is occupied by C, if that is replaced by T, it affects the posttranscriptional modification of TCF7L2 mRNA [33] . In view of this, a comprehensive case control study was performed in South Indians to address three questions.
 Is TCF7L2 gene polymorphism the cause for differences in the Type 2 diabetic susceptibility among any population?  If so, does it involve alteration in GLP-1 levels and thereby postprandial insulin secretion alone or does it have a role in altering insulin sensitivity as well?  If so, can a cut off value be set for GLP-1 levels, below which significant diabetes risk be assessed?
The three TCF7L2 genotypes were assessed among 90 newly diagnosed cases of Type 2 diabetes and 90 age and sex matched healthy volunteers. The evidence available showed that there is a significantly higher proportion of TT and TC genotypic individuals among cases when compared to controls suggesting us that T allele can increase the susceptibility to Type 2 diabetes.
To analyse, the phenotypic effect of this polymorphism, we analysed fasting and postprandial GLP-1 levels among the various genotypes. The mean GLP 1 activity among T+ genotypic individuals is lower than individuals with T-genotype, suggesting us that T polymorphism affects the GLP-1 levels. Simultaneously, to re-establish the fact that GLP-1 decrease can result in Type 2 diabetes, we compared GLP-1 levels among cases and controls, and we found GLP-1 level to be low among cases than among controls. So, the conclusion is TCF7L2 gene variation by altering the post transcriptional modification of preproglucagon gene, decreases GLP-1 levels and that increases the risk of Type 2 diabetes.
We measured fasting and postprandial insulin, calculated HOMA-IR, as an index of insulin sensitivity. We found that postprandial insulin levels were low and HOMA index was high among cases when compared to controls, proving the fact that Type 2 diabetes is characterised by not only insulin resistance but also an insulin secretory defect.
To identify the role of GLP-1 in glycemic control, we correlated GLP-1 levels with HOMA-IR, postprandial insulin and percentage rise in insulin. A positive correlation coefficient with a significant p value for % rise in postprandial insulin suggests that decrease in GLP-1 level causes a decrease in insulin secretion. A negative correlation coefficient with a significant p value for HOMA-IR suggests that decrease in GLP-1 level causes an increase in HOMA-IR or an increase in insulin resistance. Thus, GLP-1 has got a role in both insulin secretion and in sensitising the cells to insulin activity.
When an attempt was made to set up a cut off value, Receiver Operating Characteristics curve analysis has detected the cut off value of GLP-1 as 27.8pM with a sensitivity of 0.789 and specificity 0f 0.678 Thus, Genotypes TT and TC cause a decrease in fasting and postprandial GLP-1 levels, which in turn by decreasing insulin levels and by increasing insulin resistance increase the risk of Type 2 diabetes.
CONCLUSION
In conclusion, we have examined the association of the TCF7L2 genotypes and phenotypes with Type 2 diabetes and have found a significant association of T variant and low GLP-1 level among Type 2 diabetic individuals  Thus, the low GLP-1 levels and the T genotype may be an independent risk factor for Type 2 diabetes.  GLP-1 level can be used as a parameter for assessing Type 2 diabetes risk.  TCF7L2 genotype polymorphism detection and GLP-1 levels measurement can be used to customise treatment of Type 2 diabetes with gliptins which increase GLP-1 levels by inhibiting Dipeptidyl Peptidase IV, an enzyme which metabolises GLP-1.
